Alector (ALEC) Preferred Stock Liabilities (2018)
Alector's (ALEC) quarterly Preferred Stock Liabilities came in at $210.5 million in Q4 2018, little changed on a QoQ basis from $210.2 million in Q3 2018.
Alector (ALEC) Preferred Stock Liabilities (2018) Analysis & Trends
Alector (ALEC) has 1 years of Preferred Stock Liabilities data on file, last reported at $210.5 million in Q4 2018.
- On a quarterly basis, Preferred Stock Liabilities changed N/A year-over-year to $210.5 million in Q4 2018; TTM through Dec 2018 was $210.5 million, a N/A change from a year earlier, with the FY2018 full-year figure at $210.5 million, up 171.69% from the prior year.
- Preferred Stock Liabilities for Q4 2018 stood at $210.5 million, roughly flat from $210.2 million in the prior quarter.
- Over the last five years, Preferred Stock Liabilities for ALEC reached as high as $210.5 million in Q4 2018 and fell as low as $77.5 million in Q1 2018.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | - |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | - |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | - |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Alector | 164.78 Mn | -41.74 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2018 | 210.52 Mn |
| Sep 30, 2018 | 210.17 Mn |
| Jun 30, 2018 | 147.57 Mn |
| Mar 31, 2018 | 77.49 Mn |